XML 50 R43.htm IDEA: XBRL DOCUMENT v3.24.3
Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Consolidated Statements of Comprehensive Income (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues [Abstract]      
Total revenue $ 632,362 $ 801,536 $ 670,534
Costs and Expenses [Abstract]      
Cost of product revenue 353,922 345,830 279,280
Research and development 42,722 43,936 34,274
Selling, general and administrative 218,584 215,829 183,866
Contingent consideration (30,569) (28,729) 5,865
Total costs and operating expenses 584,659 576,866 503,285
Income from operations 47,703 224,670 167,249
Other income (expenses):      
Investment income 24,135 6,978 176
Interest expense (2,503) (1,162) (11,278)
Loss on extinguishment of debt (12,676) 0 0
Amortization of debt issuance costs (8,075) (1,815) (1,436)
Other income (expenses) 8,123 (9,531) (1,168)
Other income (expenses), net 9,004 (5,530) (13,706)
Income before income taxes 56,707 219,140 153,543
Income tax provision 21,111 33,181 25,252
Net income $ 35,596 $ 185,959 $ 128,291
Earnings per share:      
Basic $ 0.64 $ 3.35 $ 2.33
Diluted $ 0.63 $ 3.24 $ 2.24
Weighted average common shares outstanding:      
Basic 55,720 55,460 55,015
Diluted 56,377 57,455 57,264
Net Income (Loss) $ 35,596 $ 185,959 $ 128,291
Other comprehensive income (loss):      
Foreign currency translation adjustment (3,414) (17,508) (18,971)
Comprehensive income 32,182 168,451 109,320
Products      
Revenues [Abstract]      
Total revenue 631,979 [1] 801,183 670,319 [2]
Royalty and other revenue      
Revenues [Abstract]      
Total revenue 383 $ 353 $ 215
As Previously Reported      
Revenues [Abstract]      
Total revenue 638,764    
Costs and Expenses [Abstract]      
Cost of product revenue 353,922    
Research and development 42,722    
Selling, general and administrative 218,113    
Contingent consideration (30,569)    
Total costs and operating expenses 584,188    
Income from operations 54,576    
Other income (expenses):      
Investment income 24,135    
Interest expense (1,951)    
Loss on extinguishment of debt (12,676)    
Amortization of debt issuance costs (8,075)    
Other income (expenses) 8,123    
Other income (expenses), net 9,556    
Income before income taxes 64,132    
Income tax provision 22,555    
Net income $ 41,577    
Earnings per share:      
Basic $ 0.75    
Diluted $ 0.74    
Weighted average common shares outstanding:      
Basic 55,720    
Diluted 56,377    
Net Income (Loss) $ 41,577    
Other comprehensive income (loss):      
Foreign currency translation adjustment (3,037)    
Comprehensive income 38,540    
As Previously Reported | Products      
Revenues [Abstract]      
Total revenue 638,381    
As Previously Reported | Royalty and other revenue      
Revenues [Abstract]      
Total revenue 383    
Revenue Adjustments      
Revenues [Abstract]      
Total revenue (6,402)    
Costs and Expenses [Abstract]      
Cost of product revenue 0    
Research and development 0    
Selling, general and administrative 0    
Contingent consideration 0    
Total costs and operating expenses 0    
Income from operations (6,402)    
Other income (expenses):      
Investment income 0    
Interest expense 0    
Loss on extinguishment of debt 0    
Amortization of debt issuance costs 0    
Other income (expenses) 0    
Other income (expenses), net 0    
Income before income taxes (6,402)    
Income tax provision (1,205)    
Net income $ (5,197)    
Earnings per share:      
Basic $ (0.09)    
Diluted $ (0.09)    
Weighted average common shares outstanding:      
Basic 0    
Diluted 0    
Net Income (Loss) $ (5,197)    
Other comprehensive income (loss):      
Foreign currency translation adjustment (377)    
Comprehensive income (5,574)    
Revenue Adjustments | Products      
Revenues [Abstract]      
Total revenue (6,402)    
Revenue Adjustments | Royalty and other revenue      
Revenues [Abstract]      
Total revenue 0    
Other Adjustments      
Revenues [Abstract]      
Total revenue 0    
Costs and Expenses [Abstract]      
Cost of product revenue 0    
Research and development 0    
Selling, general and administrative 471    
Contingent consideration 0    
Total costs and operating expenses 471    
Income from operations (471)    
Other income (expenses):      
Investment income 0    
Interest expense (552)    
Loss on extinguishment of debt 0    
Amortization of debt issuance costs 0    
Other income (expenses) 0    
Other income (expenses), net (552)    
Income before income taxes (1,023)    
Income tax provision (239)    
Net income $ (784)    
Earnings per share:      
Basic $ (0.02)    
Diluted $ (0.02)    
Weighted average common shares outstanding:      
Basic 0    
Diluted 0    
Net Income (Loss) $ (784)    
Other comprehensive income (loss):      
Foreign currency translation adjustment 0    
Comprehensive income (784)    
Other Adjustments | Products      
Revenues [Abstract]      
Total revenue 0    
Other Adjustments | Royalty and other revenue      
Revenues [Abstract]      
Total revenue $ 0    
[1] 2023 revenue for filtration products includes revenue related to FlexBiosys, Inc. (“FlexBiosys”) from April 17, 2023, as well as Metenova Holding AB (“Metenova”) from October 2, 2023.
[2] 2021 revenue for filtration products includes revenue related to Polymem S.A. (“Polymem”) from July 1, 2021, as well as BioFlex Solutions LLC (“BioFlex”) and Newton T&M Corp. (“NTM”) from December 16, 2021 through December 31, 2021. 2021 revenue for proteins products includes revenue related to Avitide, Inc. (“Avitide”) from September 20, 2021 through December 31, 2021.